The pivotal IMPACT trial was a Phase 3, randomized, double-blind, multicenter, controlled study in 512 men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (CRPC).1
Primary endpoint: Overall survival
Secondary endpoint: Time to objective disease progression
The main goal of the IMPACT trial was not to lower PSA levels—it was to extend survival.
*Eligible patients were hormone refractory and had metastatic disease in the soft tissue and/or bone with evidence of progression; 18% had received prior chemotherapy (including docetaxel).
†Control was nonactivated, autologous, peripheral blood mononuclear cells.
‡Progression=radiographic evidence of disease progression.
§Autologous, peripheral blood mononuclear cells that were cryopreserved at the time of control generation and subsequently activated.
- 64% of patients in the control group, following progression, crossed over to a
nonrandomized, open-label protocol to receive an investigational autologous
immunotherapy made from cryopreserved cells1
- Treatment in the open-label protocol was at the physician’s discretion
Phase 3 IMPACT Trial Results
Learn more about survival benefit with PROVENGE therapy, and read the complete
Phase 3 IMPACT Trial results published in the New England Journal of Medicine.
- Kantoff PW, Higano CS, Shore ND, et al; for the IMPACT Study Investigators.
Sipuleucel-T immunotherapy for castrate-resistant prostate cancer. N Engl J Med.